Cargando…

PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays

Urothelial bladder cancer (UBC) patients ineligible to platinum-based chemotherapy can be treated with immune-checkpoint inhibitors (ICI) in Programmed Death Ligand 1 (PD-L1) positive cases. Although concordance exists between different PD-L1 assays, little is known on PD-L1 expression variability i...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Jong, Joep J., Stoop, Hans, Boormans, Joost L., van Leenders, Geert J.L.H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516767/ https://www.ncbi.nlm.nih.gov/pubmed/33909149 http://dx.doi.org/10.1007/s00428-021-03094-6

Ejemplares similares

Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder
por: van den Tempel, Nathalie, et al.
Publicado: (2018)

The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial
por: Rutten, V. C., et al.
Publicado: (2023)

The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder
por: van Doeveren, Thomas, et al.
Publicado: (2020)

Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?
por: Beukers, Willemien, et al.
Publicado: (2012)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Limited Funds for Bladder Cancer Research and What Can We Do About It
por: Boormans, Joost L., et al.
Publicado: (2016)

Pelvic lymph node dissection for cervical or bladder cancer: embedding residual fat tissue offers no added value
por: Vaneman, Jasmijn, et al.
Publicado: (2023)

Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer
por: Kolijn, Kimberley, et al.
Publicado: (2015)

Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

Attenuated XPC Expression Is Not Associated with Impaired DNA Repair in Bladder Cancer
por: Naipal, Kishan A. T., et al.
Publicado: (2015)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer
por: Hoogland, A. Marije, et al.
Publicado: (2016)

Military Dogs and Their Soldier Companions: The More‐than‐human Biopolitics of Leishmaniasis in Conflict‐torn Colombia
por: Pinto‐García, Lina
Publicado: (2022)

Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?
por: Bier, Simone, et al.
Publicado: (2018)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
por: Sweis, Randy F., et al.
Publicado: (2018)

Publisher Correction: Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

The prognostic value of PD‐L1 expression in upper tract urothelial carcinoma varies according to platelet count
por: Miyama, Yu, et al.
Publicado: (2018)

Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years
por: Weyerer, Veronika, et al.
Publicado: (2017)

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer
por: Kawahara, Takashi, et al.
Publicado: (2018)

Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection
por: Munari, Enrico, et al.
Publicado: (2022)

Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population‐based study from 1993 to 2017
por: van Doeveren, Thomas, et al.
Publicado: (2021)

Are invasive plants more competitive than native conspecifics? Patterns vary with competitors
por: Zheng, Yulong, et al.
Publicado: (2015)

Adaptation to Varying Salinity in Halomonas elongata: Much More Than Ectoine Accumulation
por: Hobmeier, Karina, et al.
Publicado: (2022)

Urothelial bladder afferents selectively project to L6/S1 levels and are more peptidergic than those projecting to the T13/L1 levels in female rats
por: Clodfelder-Miller, Buffie, et al.
Publicado: (2023)

Prognostic Significance of PD-L2 Expression in Association with Neutrophil-to-Lymphocyte Ratio in Urothelial Carcinoma of the Bladder
por: Hendri, Ahmad Zulfan, et al.
Publicado: (2023)

Evidence for Bladder Urothelial Pathophysiology in Functional Bladder Disorders
por: Keay, Susan K., et al.
Publicado: (2014)

Non-prostatic pathology on prostate needle-biopsy – colorectal carcinoid: a case report
por: van den Bergh, Roderick CN, et al.
Publicado: (2009)

Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial
por: van Doeveren, T., et al.
Publicado: (2018)

The varied functions of aluminium-activated malate transporters–much more than aluminium resistance
por: Palmer, Antony J., et al.
Publicado: (2016)

Significance of pigmented urothelial and non-urothelial cells in voided urine specimens: A case report and review
por: Kagan, Joseph Alan, et al.
Publicado: (2017)

A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report
por: Wang, Jianzheng, et al.
Publicado: (2021)

Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial
por: Stockem, C.F., et al.
Publicado: (2023)

Intravesical therapy for urothelial carcinoma of the bladder
por: Manoharan, M.
Publicado: (2011)

Urothelial Bladder Cancer Urinary Biomarkers
por: Noon, Aidan P, et al.
Publicado: (2014)

Role of angiogenesis in urothelial bladder carcinoma
por: Fus, Łukasz Piotr, et al.
Publicado: (2016)

Bladder melanosis with concurrent urothelial carcinoma
por: Yau, Susanna E., et al.
Publicado: (2017)

Cutaneous metastasis of bladder urothelial carcinoma
por: Hasan, Osamah, et al.
Publicado: (2019)

Giant Cell Urothelial Carcinoma of Bladder
por: Wijesinghe, Harshima Disvini, et al.
Publicado: (2021)

Molecular classification of urothelial bladder carcinoma
por: Schwarzova, Lucia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o2ffpd115ph3mbons5khs29a18